BACKGROUND: Sexually transmissible infections (STI) have been variably associated with increased risks of prostate cancer, largely in case-control studies. METHODS: In the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, we examined risk of prostate cancer in relation to serum antibodies to Chlamydia trachomatis, human papillomavirus-16 and -18, herpes simplex virus-2, cytomegalovirus, and human herpesvirus-8 in 868 cases (765 Whites and 103 Blacks) and 1,283 controls matched by race, age, time since initial screening, and year of blood draw; all blood samples were collected at least 1 year before prostate cancer diagnosis, except for 43 Black cases. We also assessed risk associated with self-reported history of syphilis and gonorrhea. RESULTS: Prevalences of the 7 STIs among controls were weakly correlated, and all were more frequent among Blacks than Whites, except for human herpesvirus-8. Among Whites, prostate cancer risk was not significantly associated with the individual infections or with their number (P(trend) = 0.1); however, men with one or more STI had slightly higher risk (odds ratio, 1.3; 95% confidence interval, 1.0-1.6). Among Blacks, excess risk was associated with IgA antibody to C. trachomatis (odds ratio, 2.1; 95% confidence interval, 1.2-3.6). CONCLUSION: This large prospective study of prostate cancer shows no consistent association with specific STIs and a borderline association with any versus none. Whether a shared response or correlated infection not directly measured underlies the weak association requires further study.
RCT Entities:
BACKGROUND: Sexually transmissible infections (STI) have been variably associated with increased risks of prostate cancer, largely in case-control studies. METHODS: In the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, we examined risk of prostate cancer in relation to serum antibodies to Chlamydia trachomatis, human papillomavirus-16 and -18, herpes simplex virus-2, cytomegalovirus, and human herpesvirus-8 in 868 cases (765 Whites and 103 Blacks) and 1,283 controls matched by race, age, time since initial screening, and year of blood draw; all blood samples were collected at least 1 year before prostate cancer diagnosis, except for 43 Black cases. We also assessed risk associated with self-reported history of syphilis and gonorrhea. RESULTS: Prevalences of the 7 STIs among controls were weakly correlated, and all were more frequent among Blacks than Whites, except for human herpesvirus-8. Among Whites, prostate cancer risk was not significantly associated with the individual infections or with their number (P(trend) = 0.1); however, men with one or more STI had slightly higher risk (odds ratio, 1.3; 95% confidence interval, 1.0-1.6). Among Blacks, excess risk was associated with IgA antibody to C. trachomatis (odds ratio, 2.1; 95% confidence interval, 1.2-3.6). CONCLUSION: This large prospective study of prostate cancer shows no consistent association with specific STIs and a borderline association with any versus none. Whether a shared response or correlated infection not directly measured underlies the weak association requires further study.
Authors: Fujie Xu; Maya R Sternberg; Benny J Kottiri; Geraldine M McQuillan; Francis K Lee; Andre J Nahmias; Stuart M Berman; Lauri E Markowitz Journal: JAMA Date: 2006-08-23 Impact factor: 56.272
Authors: Fujie Xu; Julia A Schillinger; Maya R Sternberg; Robert E Johnson; Francis K Lee; Andre J Nahmias; Lauri E Markowitz Journal: J Infect Dis Date: 2002-03-22 Impact factor: 5.226
Authors: Eric A Engels; Jonnae O Atkinson; Barry I Graubard; Geraldine M McQuillan; Christine Gamache; Georgina Mbisa; Silvia Cohn; Denise Whitby; James J Goedert Journal: J Infect Dis Date: 2007-06-04 Impact factor: 5.226
Authors: Kim N Danforth; Richard B Hayes; Carmen Rodriguez; Kai Yu; Lori C Sakoda; Wen-Yi Huang; Bingshu E Chen; Jinbo Chen; Gerald L Andriole; Eugenia E Calle; Eric J Jacobs; Lisa W Chu; Jonine D Figueroa; Meredith Yeager; Elizabeth A Platz; Dominique S Michaud; Stephen J Chanock; Michael J Thun; Ann W Hsing Journal: Carcinogenesis Date: 2007-11-13 Impact factor: 4.944
Authors: Jocelyn M Weiss; Wen-Yi Huang; Sabina Rinaldi; Thomas R Fears; Nilanjan Chatterjee; David Chia; E David Crawford; Rudolf Kaaks; Richard B Hayes Journal: Int J Cancer Date: 2007-11-15 Impact factor: 7.396
Authors: Irina Mordukhovich; Paul L Reiter; Danielle M Backes; Leila Family; Lauren E McCullough; Katie M O'Brien; Hilda Razzaghi; Andrew F Olshan Journal: Cancer Causes Control Date: 2010-12-24 Impact factor: 2.506
Authors: Miguelle Marous; Wen-Yi Huang; Charles S Rabkin; Richard B Hayes; John F Alderete; Bernard Rosner; Robert L Grubb; Anke C Winter; Siobhan Sutcliffe Journal: Cancer Causes Control Date: 2017-07-01 Impact factor: 2.506
Authors: Siobhan Sutcliffe; Cathee Till; Charlotte A Gaydos; Frank J Jenkins; Phyllis J Goodman; Ashraful M Hoque; Ann W Hsing; Ian M Thompson; Jonathan M Zenilman; William G Nelson; Angelo M De Marzo; Elizabeth A Platz Journal: Cancer Causes Control Date: 2012-07-19 Impact factor: 2.506
Authors: Siobhan Sutcliffe; Raphael P Viscidi; Cathee Till; Phyllis J Goodman; Ashraful M Hoque; Ann W Hsing; Ian M Thompson; Jonathan M Zenilman; Angelo M De Marzo; Elizabeth A Platz Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-02 Impact factor: 4.254
Authors: Siobhan Sutcliffe; John F Alderete; Calvin Neace; Patrick A Joyce; Charlotte A Gaydos; James I A Huth; Lorelei A Mucci; Lisa B Signorello Journal: Cancer Causes Control Date: 2015-07-30 Impact factor: 2.506
Authors: Iona Cheng; John S Witte; Steven J Jacobsen; Reina Haque; Virginia P Quinn; Charles P Quesenberry; Bette J Caan; Stephen K Van Den Eeden Journal: PLoS One Date: 2010-01-15 Impact factor: 3.240